Cited by 134Advanced Glycation End Products researchDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes

Open access
Koska, Juraj, Saremi, Aramesh, Howell, Scott, Bahn, Gideon, De Courten, Barbora, Ginsberg, Henry, Beisswenger, Paul J., Reaven, Peter D. +1 more·2018·Diabetes Care

Abstract

OBJECTIVE: The goal of this study was to determine whether plasma levels of advanced glycation end products (AGE) and oxidation products (OP) predict the incidence of cardiovascular disease (CVD) in type 2 diabetes. RESEARCH DESIGN AND METHODS: Five specific AGE (methylglyoxal hydroimidazolone, carboxymethyl lysine, carboxyethyl lysine, 3-deoxyglucosone hydroimidazolone, and glyoxal hydroimidazolone) and two OP (2-aminoadipic acid and methionine sulfoxide [MetSO]) were measured at baseline in two intensive glucose-lowering studies: 1) a subcohort of the Veterans Affairs Diabetes Trial (VADT) (n = 445) and 2) a nested case-control subgroup from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (n = 271). RESULTS: Increased levels of several AGE and OP were associated with older age, decreased kidney function, previous CVD, and longer diabetes duration, but not with hemoglobin A1c. In the VADT, increased risk of incident CVD events (n = 107) was associated with lower MetSO after adjusting for age, race/ethnicity, sex, prior CVD event, kidney function, treatment assignment, and diabetes duration (hazard ratio [HR] 0.53; 95% CI 0.28–0.99; P = 0.047). Individuals with both low MetSO and high 3-deoxyglucosone hydroimidazolone concentrations were at highest risk for CVD (HR 1.70; P = 0.01). In the ACCORD study, those with incident CVD events (n = 136) had lower MetSO (by 14%; P = 0.007) and higher glyoxal hydroimidazolone and carboxymethyl lysine (by 18% and 15%, respectively; P = 0.04 for both); however, only the difference in MetSO remained significant after adjustment for prior CVD event (P = 0.002). CONCLUSIONS: Lower levels of MetSO and higher levels of select AGE are associated with increased incident CVD and may help account for the limited benefit of intensive glucose lowering in type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc17-1740

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Higher levels of circulating AGEs are positively correlated with the incidence of cardiovascular disorders and severity of coronary atherosclerosis and coronary artery disease independent of diabetic status.

    “Additionally, higher levels of circulating AGEs are positively correlated with the incidence of cardiovascular disorders and severity of coronary atherosclerosis and coronary artery disease independent of diabetic status62–64, suggesting a causal role of AGEs in cardiovascular diseases.”
  • AGEs have a causal role in cardiovascular diseases.

    “Additionally, higher levels of circulating AGEs are positively correlated with the incidence of cardiovascular disorders and severity of coronary atherosclerosis and coronary artery disease independent of diabetic status62–64, suggesting a causal role of AGEs in cardiovascular diseases.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Koska, J., Saremi, A., Howell, S., Bahn, G., De Courten, B., Ginsberg, H., Beisswenger, P. J., Reaven, P. D., & for the VADT Investigators
Affiliations
  • Phoenix VA Health Care System, Phoenix, AZ
  • Phoenix VA Health Care System (US)
  • PreventAGE Health Care (United States) (US)
  • Edward Hines, Jr. VA Hospital (US)
  • Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia
  • Columbia University (US)
Venue
Diabetes Care
Published
2017-12-05
Volume
41
Issue
3
Pages
570-576
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2771721456
Cited by
134
References
35
Citations by year
2026: 7 · 2025: 19 · 2024: 11 · 2023: 15 · 2022: 26 · 2021: 15 · 2020: 15 · 2019: 19 · 2018: 7
FWCI
9.32
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • RMIT Research Repository (RMIT University Library) (submittedVersion, other-oa)
  • Figshare (submittedVersion)
Funders
  • Veterans Affairs Cooperative Studies Program, Department of Veterans Affairs Office of Research and Development
  • National Institutes of Health (R01-HL110418, R01-067690, 5R01-094775)
  • American Diabetes Association
  • National Institute of Diabetes and Digestive and Kidney Diseases (4R44-DK101226-01A1)
  • National Heart Foundation Future Leader Fellowship (100864)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
advanced glycation end products, oxidation products, type 2 diabetes, cardiovascular disease incidence, methionine sulfoxide, carboxymethyllysine, 2-aminoadipic acid, tight glycemic control, cardiovascular risk prediction
MeSH terms
Aged, Cardiovascular Diseases, Cholesterol, Deoxyglucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Imidazoles, Lysine, Male, Methionine, Middle Aged, Oxidation-Reduction, Pyruvaldehyde, Risk Factors, Triglycerides, 2-Aminoadipic Acid, Cohort Studies, Body Mass Index, Incidence, Case-Control Studies, Glycation End Products, Advanced

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review